Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06471543 · ClinicalTrials.gov registry record · Phase 1
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
A Phase 1 study of Hypertriglyceridemia and Familial Chylomicronemia Syndrome, sponsored by Ikaria Bioscience Pty.
- Active
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 10
- Study locations
NCT06471543 is a Phase 1 study of Hypertriglyceridemia and Familial Chylomicronemia Syndrome that is active but no longer recruiting, run by Ikaria Bioscience Pty. The registered enrollment target is 108 participants, below the 172-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (37% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT06471543, a Phase 1 study of Hypertriglyceridemia and Familial Chylomicronemia Syndrome, is active but no longer recruiting, sponsored by Ikaria Bioscience Pty.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN0361 in Adult healthy subjects and Adult Hypertriglyceridemic Subjects.
Conditions Studied
Interventions
- DRUG RN0361
Study Locations (10)
Texas
- Synergy Groups Medical - Houston
- Tranquil - Webster
Queensland
- University of the Sunshine Coast Clinical Trials - Morayfield
- University of the Sunshine Coast Clinical Trials, Sippy Downs - Sippy Downs
Victoria
- Altona Clinical Research - Altona N.
- Nucleus Network Melbourne - Melbourne
Florida
- TBC Research LLC, - Tamarac
Kentucky
- Versailles Family Medicine / Avacare - Versailles
Minnesota
- Axis Clinicals USA - Dilworth
Utah
- Ogden Clinic, Mountain View / Avacare - Pleasant View
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06471543
The ClinicalTrials.gov registry entry for NCT06471543 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 172-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (37% lower). The listed sponsor is Ikaria Bioscience Pty, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertriglyceridemia appearing as the primary indexed condition, and to 1 intervention - of which RN0361 is the first listed.
NCT06471543 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Texas, Queensland, Victoria.
Frequently Asked Questions
What is clinical trial NCT06471543 about?
NCT06471543 is a clinical study titled "Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN0361 in Adult healthy subjects and Adult Hypertriglyceridemic Subjects.
What is the current status of trial NCT06471543?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2024-09-30. Estimated completion is 2026-08-26.
What conditions does trial NCT06471543 study?
This clinical trial studies the following conditions: Hypertriglyceridemia, Familial Chylomicronemia Syndrome.
What interventions are being tested in trial NCT06471543?
The interventions under investigation include: RN0361 (DRUG).
Who is sponsoring clinical trial NCT06471543?
This trial is sponsored by Ikaria Bioscience Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06471543 being conducted?
This trial has 10 study locations across Florida, Kentucky, Minnesota, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
COMPLETED · Phase 1
-
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
COMPLETED · Phase 1
-
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
COMPLETED · Phase 1
-
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects
COMPLETED · Phase 1
-
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
COMPLETED · Phase 1
-
Study of Gemcabene in Adults With FPLD
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.